Controlled Trial of Valacyclovir in Infectious Mononucleosis
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The hypothesis is that an antiviral drug (valacyclovir) will reduce the amount of
Epstein-Barr virus (EBV) in the mouths of university students with infectious mononucleosis
(mono) while being a safe drug. Because EBV is the cause of mono, it is expected that
reduction of the amount of virus could result in faster recovery from the disease.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute